hOMSC300

Phase 1Biologic

CCytora Ltd.

hOMSC300 is one of 29 biologic programs targeting Multiple System Atrophy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple System AtrophyActive, not recruiting

Multiple System AtrophyPhase 1

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Northera

Rifadin

Rilutek

AAzurity Pharmaceuticals

Sudafed

Rifampicin

1 6

Byetta

AstraZeneca

Phase 2

—7

Rapamune

PPrism Pharmaceuticals

Phase 2

1 8

Lithobid

SSolvay Pharmaceuticals

Phase 2

1 9

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 10

Lu AF95245

Lundbeck

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

Active, not recruiting·CCytora Ltd.·Phase 1·NCT05698017·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hOMSC300. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hOMSC300 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hOMSC300. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cytora Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCytora Ltd.

hOMSC300

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News